BiotechTube
Home/Pipeline/VTP-03

VTP-03

Oncology (unspecified)

Pre-clinicalActive

Key Facts

Indication
Oncology (unspecified)
Phase
Pre-clinical
Status
Active
Company
Var2 Pharmaceuticals

About Var2 Pharmaceuticals

Var2 Pharmaceuticals is pioneering a novel oncology platform based on targeting oncofetal chondroitin sulfate (ofCS), a carbohydrate modification expressed in over 95% of cancers but absent in most healthy tissues. Its lead assets, called Vartumabs, are proprietary antibodies with high affinity for ofCS, being developed in multiple formats including antibody-drug conjugates (ADCs), bispecifics, and cell therapies. The company is clinical-stage, having initiated a Phase 0 imaging trial in late 2024 and planning a Phase I/IIA trial for its lead ADC candidate in 2027.

View full company profile

Therapeutic Areas

Oncology

Other Oncology (unspecified) Drugs

DrugCompanyPhase
Oncology Vaccine ProgramCHAIN BiotechPre-clinical
ARX305NovoCodex BiopharmaceuticalsPhase 1
ARX788NovoCodex BiopharmaceuticalsPhase 1
Cancer Immunotherapy NanotherapeuticFlashpoint TherapeuticsPhase 1
GRWD5769Greywolf TherapeuticsPhase 1/2
Platform-derived Program(s)Immuto ScientificDiscovery/Pre-clinical
MBT Oncology ProgramIonic PharmaceuticalsPre-clinical
ISB 2301Ichnos Glenmark InnovationPreclinical
GRC 65327Ichnos Glenmark InnovationPreclinical
Platform-Derived PipelinePhinomicsDiscovery/Pre-clinical
Lead Small-Molecule InhibitorEris BiotechPre-clinical
Orotecan™Edison OncologyPhase 1/2a